Osteosarcoma is NOT a contraindication to GLP-1 receptor agonist therapy
The only absolute contraindications to GLP-1 receptor agonists are a personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN2)—osteosarcoma is not among these contraindications. 1, 2, 1
Understanding the Contraindications
The FDA Black Box Warning for GLP-1 receptor agonists specifically addresses thyroid C-cell tumors, not bone cancers like osteosarcoma 1. This warning stems from rodent studies showing increased thyroid C-cell tumors, though medullary thyroid carcinoma has not been shown to be caused by GLP-1 RAs in humans 2.
Specific Contraindications for GLP-1 RAs:
- Personal history of medullary thyroid carcinoma
- Family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
These contraindications apply to all longer-acting GLP-1 receptor agonists (semaglutide, liraglutide, exenatide ER, and dulaglutide), but notably not to twice-daily exenatide and lixisenatide 2.
Cancer Risk Evidence with GLP-1 RAs
Recent high-quality research actually suggests protective effects against certain cancers rather than increased risk:
A 2025 study of 86,632 matched adults found GLP-1 RA use was associated with significantly lower overall cancer risk (HR 0.83,95% CI 0.76-0.91) compared with nonusers 3
Another 2024 study of 1.65 million patients with type 2 diabetes showed GLP-1 RAs were associated with risk reduction in 10 of 13 obesity-associated cancers compared with insulin, including pancreatic, hepatocellular, ovarian, colorectal, and kidney cancers 4
Meta-analyses confirm that GLP-1 receptor therapies do not increase cancer incidence and may lower risk in some cases 5
Clinical Considerations
Pancreatitis is mentioned as a rare association, and prescribing information generally states these agents have not been studied in persons with a history of pancreatitis—consider other therapies in such patients 2. However, this is distinct from cancer contraindications.
The FDA has explicitly stated that persons taking a GLP-1 RA do not need to be monitored for medullary thyroid carcinoma (e.g., with calcitonin levels) 2.
Bottom Line
You can safely prescribe GLP-1 receptor agonists to patients with osteosarcoma. Screen only for the specific contraindications: personal/family history of MTC or MEN2 syndrome. The thyroid-specific warning does not extend to other malignancies, including bone cancers like osteosarcoma.